DexCom (NASDAQ:DXCM) and PAVmed (NASDAQ:PAVM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.
Insider & Institutional Ownership
6.7% of PAVmed shares are owned by institutional investors. 1.8% of DexCom shares are owned by insiders. Comparatively, 29.2% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a breakdown of current ratings and target prices for DexCom and PAVmed, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
DexCom presently has a consensus target price of $127.67, indicating a potential downside of 2.87%. PAVmed has a consensus target price of $5.00, indicating a potential upside of 342.48%. Given PAVmed’s stronger consensus rating and higher possible upside, analysts clearly believe PAVmed is more favorable than DexCom.
Volatility and Risk
DexCom has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, PAVmed has a beta of -0.67, suggesting that its stock price is 167% less volatile than the S&P 500.
Earnings & Valuation
This table compares DexCom and PAVmed’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|DexCom||$718.50 million||16.16||-$50.20 million||($0.58)||-226.62|
PAVmed has lower revenue, but higher earnings than DexCom. DexCom is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.
This table compares DexCom and PAVmed’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
PAVmed beats DexCom on 9 of the 13 factors compared between the two stocks.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.